Valuation: ABVC BioPharma, Inc.

Market Cap 25.92M 23.15M 21.54M 19.59M 36.99M 2.51B 37.15M 259M 102M 1.28B 97.35M 95.22M 4.1B P/E 2024
-1.4x
P/E 2025 -5.42x
Enterprise Value 28.65M 25.59M 23.8M 21.65M 40.88M 2.77B 41.06M 286M 112M 1.41B 108M 105M 4.54B EV / Sales 2024
19.8x
EV / Sales 2025 -
Free-Float
79.73%
Yield 2024 *
-
Yield 2025 -
1 day+2.04%
1 week-0.99%
Current month-5.66%
1 month+2.44%
3 months-33.77%
6 months-30.07%
Current year-53.05%
1 week 0.93
Extreme 0.929
1.05
1 month 0.93
Extreme 0.929
1.23
Current year 0.71
Extreme 0.7069
2.43
1 year 0.71
Extreme 0.7069
3.16
3 years 0.4
Extreme 0.4
5.48
5 years 0.4
Extreme 0.4
116.9
10 years 0.4
Extreme 0.4
378
Manager TitleAgeSince
Chief Executive Officer 40 21/06/2023
Chief Tech/Sci/R&D Officer 72 15/06/2023
Director TitleAgeSince
Chairman 39 01/07/2015
Director/Board Member 65 23/11/2017
Director/Board Member 55 23/11/2017
Date Insider Type Main position Quantity % Market Cap. Importance
5/20/22 A Other

Chairman

7,908,805 26.0954%
8/2/21 A Other

Director

5,949 0.0243%
8/2/21 A Other

Chief Executive Officer

18,404 0.0752%
Change 5-day change 1-year change 3-year change Capi.($)
+2.04%-0.99%-67.11%+12.36% 25.92M
-2.59%-5.70%+50.69%+86.86% 70.61B
+3.23%-10.67%+6.27%+53.70% 51.01B
+1.56%+1.17%+8.49%+31.81% 48.1B
+0.39%+0.65%+31.14%+28.97% 42.78B
+0.87%-8.17%+293.37%+642.41% 40.67B
+1.24%-1.01%+10.74%+100.64% 40.3B
-2.13%-1.64%+8.63%+46.88% 30.59B
-0.46%-1.28%+42.23%+20.34% 28.16B
+5.32%+0.06%-5.00%-12.78% 24.36B
Average +0.95%-2.78%+37.95%+101.12% 37.66B
Weighted average by Cap. +0.56%-2.94%+51.34%+115.56%

Financials

2024 2025
Net sales 510K 455K 423K 385K 727K 49.32M 730K 5.1M 2M 25.14M 1.91M 1.87M 80.69M -
Net income -4.9M -4.38M -4.07M -3.71M -7M -475M -7.03M -49.03M -19.21M -242M -18.41M -18.01M -776M -7.91M -7.06M -6.57M -5.98M -11.28M -765M -11.33M -79.08M -30.98M -390M -29.7M -29.05M -1.25B
Net Debt 2.88M 2.57M 2.39M 2.18M 4.11M 279M 4.13M 28.82M 11.29M 142M 10.82M 10.59M 456M 2.73M 2.44M 2.27M 2.06M 3.89M 264M 3.91M 27.27M 10.69M 135M 10.24M 10.02M 432M
Projected Income Statement - Annual - ABVC BioPharma, Inc.
Logo ABVC BioPharma, Inc.
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Employees
-
Date Price Change Volume
09/10/26 $1.000 +2.04% 41,465
08/10/26 $0.9800 -2.00% 45,312
07/10/26 $1.000 +3.09% 52,748
06/10/26 $0.9700 -1.02% 92,418
05/10/26 $0.9800 -2.97% 93,532
  1. Stock Market
  2. Stocks
  3. ABVC Stock